Moreover, elevated serum ammonia levels have been observed in CRC patients (272), with an ammonia-related gene signature correlating with poorer prognosis and lack of response to ICIs, suggesting that targeting tumor-associated ammonia could enhance the efficacy of immunotherapy, including PD-L1 inhibitors. This evidence concerns the gene CD274 and colorectal carcinoma.